The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Probes and Styli Are Becoming Smarter
Probes and styli are vital for smart manufacturing, evolving into advanced sensors that enhance automation and quality control.…
Implementing Data Governance in the Age Of Generative AI
Role of Data Governance in Generative AI How does GenAI Support Data Governance? Ensuring Better Data Governance When…
Metrology: The Science of Correct Decision Making
Metrology significantly impacts our daily lives, and without it, many would argue that societal advancement would not be…